Trevenans

Researchers are conducting a global study to understand the impact of moderate to severe alopecia areata (AA), non-segmental vitiligo (NSV), and hidradenitis suppurativa (HS) on adolescents and adults. This study aims to assess the burden these conditions place on patients' quality of life and daily functioning in a large real-world population. The study involves participants diagnosed by a physician with one of the three conditions: AA, NSV, or HS. There are no interventional treatments or medications being tested in this study, as it is observational in nature. Data collection focuses on patient-reported outcomes and measures that evaluate disease severity and its effects. Participants will complete various questionnaires and assessments related to their condition, such as the Alopecia Areata Symptom Impact Scale (AASIS) for AA, the Severity of Alopecia Tool (SALT) for scalp hair loss in AA, the Facial Vitiligo Area Scoring Index (F-VASI) and Vitiligo Quality of Life Score (VitiQoL) for vitiligo, and the Dermatology Life Quality Index (DLQI) and International Hidradenitis Suppurativa Severity Scoring System (IHS4) for HS. These tools help researchers understand how symptoms affect quality of life and disease severity. The study collects information up to the day of the study visit.

This research aims to develop and evaluate a new tool designed to assess the condition of the oral cavity in adult patients who are orally intubated in intensive care units. Oro-tracheal intubation often causes lesions in the mouth and throat, which can affect the patient's hospital stay and quality of life. Currently, there are no specific oral assessment tools tailored for these patients, making this new tool necessary to improve care and monitoring. The study involves using the newly developed Mouth Assessment Tool (MAT), which will be applied by nurses to assess the oral condition of patients undergoing oro-tracheal intubation in intensive care. This tool has been designed with input from experts in intensive care, oral health, hygiene, wound healing, and patient partners to ensure relevance and accuracy for daily clinical use. The evaluation focuses on the tool's metrological performance, meaning its accuracy and reliability in assessing oral health in this specific patient group. Participants will be assessed at inclusion (Day 0) using the MAT by a nurse. Researchers will monitor and evaluate the tool's effectiveness in measuring oral health status accurately. The study includes patients aged 18 or older who are intubated and admitted to adult intensive care units. Consent is obtained from patients or their legal representatives. The study aims to ensure that this new tool can support better oral care and potentially improve patient outcomes in intensive care settings.

Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to standard care in adults hospitalized with severe community-acquired pneumonia (sCAP) who require invasive mechanical ventilation. This phase III, randomized, placebo-controlled, double-blind, multi-center trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes substudies to understand the pharmacokinetics and pharmacodynamics of trimodulin. Participants will be randomly assigned to receive either trimodulin or placebo via intravenous infusion once daily for five consecutive days alongside standard care. After the treatment phase, patients will be followed for up to 23 days, with an end-of-follow-up visit or telephone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, followed by a final visit or call on day 91. During the study, participants will undergo various assessments including monitoring of mortality rates up to day 29, clinical evaluations, and safety monitoring. Researchers will collect data on inflammation markers and other health parameters. Follow-up contacts and visits will ensure ongoing evaluation of patient status and adverse events throughout the study period, which may last up to 91 days or longer depending on hospital discharge timing.

Researchers are exploring how dietary sodium intake may affect disease activity in people with axial spondyloarthritis, including both radiographic and non-radiographic types, as well as psoriatic arthritis. The study aims to understand the connection between salt consumption and these inflammatory joint conditions, including the response to certain anti-inflammatory treatments. Participants will have their salt intake measured without any intervention or change to their diet. This observational approach focuses on recording sodium consumption on specific days to analyze its relationship with disease activity and therapeutic response to anti-IL-17A agents. During the study, participants will provide data on their sodium intake on the day they join the study and on the following Monday and Tuesday. Researchers will monitor disease activity alongside sodium consumption and treatment response. The study includes adults aged 18 to 80 years and involves a monitoring period covering these specific days to assess the influence of salt intake on their condition.

Researchers are evaluating the safety of trifluridine/tipiracil as a replacement for fluoropyrimidine-based chemotherapy in patients with metastatic colorectal or gastroesophageal cancer who have dihydropyrimidine dehydrogenase (DPD) deficiency. This phase II trial aims to determine if this alternative chemotherapy is safer, whether combining it with other treatments improves safety, progression-free survival, overall survival, response rates, disease control, and quality of life. Participants receive trifluridine/tipiracil orally twice daily for five days, combined with intravenous oxaliplatin every two weeks. Depending on cancer type, they also receive either panitumumab or bevacizumab for colorectal adenocarcinomas, or nivolumab or trastuzumab for gastroesophageal adenocarcinomas. The treatment cycle repeats every 14 days. Throughout the study, participants undergo CT scans every two months until their disease progresses and complete quality of life questionnaires every two months for up to six months. Optional blood samples may be collected for genetic and pharmacokinetic analyses. The main outcome measured is treatment-specific safety over one month. Participants are closely monitored with scheduled visits, laboratory tests, and other assessments during their involvement.